| Code | CSB-RA023441MB2HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is a research-grade biosimilar to PPMX-T003, designed to specifically target TFRC (Transferrin Receptor, also known as CD71 or TfR1). TFRC is a transmembrane glycoprotein essential for cellular iron uptake through receptor-mediated endocytosis of transferrin-bound iron. This receptor plays a critical role in cell proliferation and metabolism, with expression levels significantly elevated in rapidly dividing cells. TFRC overexpression is associated with various malignancies including leukemias, lymphomas, and solid tumors, making it a valuable marker for cancer research. Additionally, TFRC is implicated in neurological disorders, hereditary hemochromatosis, and serves as an entry point for certain pathogens.
PPMX-T003 is an investigational anti-TFRC antibody designed to efficiently bind and internalize cancer cells that highly express TFRC within the tumor, thereby precisely delivering the conjugated cytotoxic drug to the interior of the tumor, achieving targeted killing. PPMX-T003 has been utilized in oncology research and studies investigating iron metabolism disorders. This biosimilar provides researchers with a reliable tool for investigating TFRC expression patterns, exploring iron homeostasis mechanisms, and evaluating therapeutic strategies targeting highly proliferative cells. The antibody supports diverse experimental approaches in cancer biology, hematology, and cellular metabolism research.
There are currently no reviews for this product.